A human neuronal model of Niemann Pick C disease developed from stem cells isolated from patient’s skin
- Natascha Bergamin†1,
- Andrea Dardis†2,
- Antonio Beltrami1,
- Daniela Cesselli1,
- Silvia Rigo1,
- Stefania Zampieri2,
- Rossana Domenis1,
- Bruno Bembi2 and
- Carlo Alberto Beltrami1Email author
© Bergamin et al.; licensee BioMed Central Ltd. 2013
Received: 7 September 2012
Accepted: 14 February 2013
Published: 21 February 2013
Niemann Pick C (NPC) disease is a neurovisceral lysosomal storage disorder due to mutations in NPC1 or NPC2 genes, characterized by the accumulation of endocytosed unesterified cholesterol, gangliosides and other lipids within the lysosomes/late endosomes. Even if the neurodegeneration is the main feature of the disease, the analysis of the molecular pathways linking the lipid accumulation and cellular damage in the brain has been challenging due to the limited availability of human neuronal models.
The aim of this study was to develop a human neuronal model of NPC disease by inducing neuronal differentiation of multipotent adult stem cells (MASC) isolated from NPC patients.
Stem cells were isolated from 3 NPC patients and 3 controls both from skin biopsies and previously established skin fibroblast cultures. Cells were induced to differentiate along a neuronal fate adapting methods previously described by Beltrami et al, 2007. The surface immunophenotype of stem cells was analyzed by FACS. Stem cell and neuronal markers expression were evaluated by immunofluorescence. Intracellular accumulation of cholesterol and gangliosides were assessed by filipin staining and immunofluorescence, respectively. A morphometric analysis was performed using a Neurite outgrowth image program.
After 3 passages in selective medium, MASC isolated either from skin biopsies or previously established skin fibroblast cultures displayed an antigenic pattern characteristic of mesenchymal stem cells and expressed the stem cell markers Oct-4, Nanog, Sox-2 and nestin. A massive lysosomal accumulation of cholesterol was observed only in cells isolated from NPC patients. After the induction of neural differentiation, remarkable morphologic changes were observed and cells became positive to markers of the neuronal lineage NeuN and MAP2. Differentiated cells from NPC patients displayed characteristic features of NPC disease, they showed intracellular accumulation of unesterified cholesterol and GM2 ganglioside and presented morphological differences with respect to cells derived from healthy donors.
In conclusion, we generated a human neuronal model of NPC disease through the induction of differentiation of stem cells obtained from patient’s easily accessible sources. The strategy described here may be applied to easily generate human neuronal models of other neurodegenerative diseases.
KeywordsNiemann Pick C Human neuronal model Adult stem cells Neuronal differentiation
Niemann Pick C [NPC-MIM 257220; MIM607625] disease is a neurodegenerative lysosomal storage disorder due to mutations in NPC1 or NPC2 genes, characterized by the accumulation of endocytosed unesterified cholesterol, gangliosides and other lipids within the lysosomes/late endosomes. Both proteins are involved in the intracellular trafficking of cholesterol and other lipids. Thus, the deficiency of either of them leads to the accumulation of the endocytosed unesterified cholesterol, gangliosides and other lipids within the lysosome/late endosome compartment .
Clinically, NPC disease presents a highly variable phenotype ranging from fetal to adult age. Even though initial manifestations are typically systemic, including liver and spleen enlargement, the disease has been classified according to the age at onset of neurological symptoms in: severe infantile form (onset before 2 y of age), late infantile form (onset between 3-5 y of age), juvenile form (onset between 5 and 16 y) and adult form (onset at age>16 y) [1, 2].
Approximately 95% of NPC patients present mutations in NPC1 gene (MIM 607623; chr 18q11-q12) [3, 4], which encodes a membrane glycoprotein of 1,278 amino acids containing 13 transmembrane domains and localized in late endosomes . The other 5% of patients present mutations in NPC2 gene (MIM 601015; chr 14q24.3)  encoding a soluble 151 amino acid protein that is present in the lumen of lysosomes.
Despite the progress in characterizing the biochemical and genetic defects in NPC disease, the mechanisms underlying the pathophysiology of this disorder are not clear and the currently available therapeutic interventions are limited. In particular, the analysis of the molecular pathways linking the lipid accumulation and cellular damage in the brain has been challenging due to the limited availability of neuronal models.
Two mouse models of NPC disease have been described and used to study NPC pathogenesis, the BALB\c NPC  and the Npc1 (nmf164) mouse . The naturally occurring BALB\c NPC mouse recapitulates the main features of human pathology . However, while this model presents a very severe phenotype, most NPC patients present with a less severe form of the disease. This issue is particularly relevant when this model is used to test new potential therapies since the very acute nature of the BALB\c NPC mouse model may mask the potential benefits of therapies that could be useful in a clinical setting in patients. Recently, a new mouse model of NPC disease, Npc1 (nmf164) carrying a c.3163A>G mutation that results in an aspartate to glycine change at position 1005 (D1005G), has been generated. This mutant mouse displays a slower development of the NPC phenotype than the BALB\c NPC mouse. Therefore, it may represent a good model for the late-onset, slower progressing forms of NPC disease . However, it is worth noting that some characteristic features of NPC human neurons are not present in mice, suggesting important species differences between mice and human NPC neurons [9–11].
Many studies have been performed in peripheral cells in culture. However, the obtained results might not be extrapolated to neuronal cells since the pattern of accumulated lipids is quite different between peripheral and central tissues .
Recent advances in human stem cell biology and the optimization of protocols for in vitro differentiation of stem cells into different cell lineages have opened new possibilities for generating disease cellular models.
Pluripotent cells have the ability to form all the body's cell lineages, including germ cells and some extra-embryonic cell types . The analyisis of blastocyst chimerism and tetraploid aggregation followed by gestation are the most appropriate tests employed to assess mouse stem cell pluripotency . Human stem cell pluripotency cannot be tested for their ability to generate fully functional germ cells in vivo without raising ethical concern. Consequently, a surrogate test for human stem cell pluripotency is teratoma formation upon administration to a receptive animal . Interestingly, a number of reports have demonstrated that adult human tissues host widely multipotent cells. Although these latter are able to differentiate, both in vitro and in vivo[13, 14], into mesodermal , ectodermal  and endodermal  derivatives, even at a clonal level , they do not form either teratomas in vivo or contribute to the germ cell lineages, thus not entirely fulfilling the criteria for pluripotency. This may be secondary to epigenetic differences between adult and embryonic stem cells .
Our group has described a highly reproducible method to isolate, from different adult human tissues (heart, liver and bone marrow), a population of multipotent stem cells (named Multipotent Adult Stem Cells or MASC), which express several pluripotent state specific transcription factors (i.e. OCT4, Nanog, Sox2, and Rex1), display high levels of telomerase activity and show all the characteristics of stem cells, such as clonogenicity and self renewal. Furthermore, they present a highly similar gene expression profile, irrespectively from the tissue of origin and they maintain the ability to differentiate along some derivatives of the 3 germ layers, including neuroectoderm .
The aim of this study was to develop a human neuronal model of NPC disease by inducing neuronal differentiation of stem cells isolated from skin biopsies or fibroblasts in culture obtained from NPC patients.
Specimens from 3 patients affected by NPC disease (two of them were siblings) and 3 normal controls have been used in this study. Samples from a patient affected by Sandhoff disease were used as positive control for ganglioside accumulation assays.
All 3 NPC patients presented the classical biochemical phenotype characterized by massive lysosomal/late endosomes accumulation of unesterified cholesterol in cultured fibroblasts. The diagnosis was confirmed by sequencing both NPC1 and NPC2 genes. All patients had mutations in the NPC1 gene. The two affected siblings presented the c.3182T>C (P.I1061T)/c.3182T>C (p.I1061T) genotype, while the third unrelated NPC patient presented the c.2795+1G>C/c.3493G>A (p.V1165M) genotype. This study was approved by the ethical committee of the University Hospital “S. Maria della Misericordia” and written consent was obtained from all subjects.
Stem cell selection and culture
Stem cell enriched cultures were obtained, both from skin biopsies and from already established skin fibroblast cultures at early passages (P1, P2, P3), adapting the methods previously described [19, 20].
Briefly, skin biopsies were minced and digested with 0.04% of collagenase type I (Sigma-Aldrich) for 15 minutes at 37°C. Cell suspension was filtered through a 40 μm nylon membrane (Dako) and 4 × 104 cells/mm2 were plated onto fibronectin coated dishes (10 μg/100 mm plate, from Sigma-Aldrich). In alternative, 2 × 106 cells directly isolated from human skin biopsies or 1 × 106 cells obtained from confluent primary skin fibroblast cultures, were seeded onto 100 mm plates coated with fibronectin and expanded at least for three passages in a selective media composed of 60% Dulbecco’s Modified Eagle medium (DMEM)/40% MCDB-201 (Sigma-Aldrich) supplemented with 1 mg/ml Linoleic Acid-BSA (Sigma-Aldrich);10-9 M dexamethasone (Sigma-Aldrich); 10-4 M Ascorbic acid-2 phosphate (Sigma-Aldrich); 1X Insulin-transferrin-sodium selenite (Sigma-Aldrich); 2% fetal bovine serum (FBS), (STEMCELL Technologies), 10 ng/ml human PDGF-BB (Peprotech EC); 10 ng/ml human EGF (Peprotech EC). Medium was replaced every 4 days and cells were split when they reached 70/80% confluence.
Single cell cloning
Stem cells, at the third passage in culture (P3), obtained from healthy donors (n = 600 cells) and NPC patients (n = 600 cells) were individually deposited directly into fibronectin-coated wells of 96-well plates (Falcon, BD-Biosciences, Italy) with an automated cell sorter (FACSAria, BD), and cultured in expansion medium supplemented with 10% FBS [19, 20]. To determine sorting efficiency and to verify if any well was seeded with more than one cell, we utilized the Vybrant CFDA SE (CFSE) as a cell tracker (Molecular Probes, Invitrogen). Wells were examined twice a week in order to determine the fraction of cells able to give rise to proliferating clones.
Muscle cell- and endothelial cell- differentiation was achieved plating 0.5 to 1 × 104/cm2 cells in expansion medium containing 5% FBS (Sigma-Aldrich), 10 ng/mL bFGF, 10 ng/mL VEGF, and 10 ng/mL IGF-1 (all from Peprotech EC), but not EGF. Cells were allowed to become confluent and cultured for up to 2 weeks with medium exchanges every 4 days.
Hepatocytic differentiation was induced growing cells for two weeks at high density (2 × 104/cm2) onto fibronectin coated coverslips in a medium containing 0.5% FBS, 10 ng/ml FGF-4 and 20 ng/ml HGF (both from Peprotech EC).
For neurogenic differentiation, stem cells obtained after 3 passages in selective medium, were seeded at a density of 8000 cells/cm2 into 96 multiwell plates (BD Biosciences) or on coverslips. The differentiation protocol was adapted from a method previously described [19, 20]. Briefly, cells were plated in medium containing DMEM-HG with 10% FBS (called N1 medium). After 24 hours the DMEM-HG was replaced with fresh medium supplemented with 1% of B27 (Invitrogen), 10 ng/ml EGF (Peprotech) and 20 ng/ml bFGF (Peprotech) (called N2 medium) for 5 days. Thereafter, cells were incubated for 24/48 hours in DMEM supplemented with 5 μg/ml insulin, 200 μM of indomethacin and 0.5 mM IBMX (all from Sigma-Aldrich) without FBS (called N3 medium).
Flow cytometry analysis
After at least 3 passages in selective medium, stem cells were detached and stained with the following primary conjugated antibodies: CD10, CD13, CD29, CD49a, CD49b, CD49d, CD90, CD73, CD44, CD45, HLA-DR, CD117, CD34, CD271 (BD Biosciences), CD105, CD66e, KDR (Serotech), CD133 (Miltenyi Biotec), CXCR4, (R&D), ABCG-2 (Chemicon International). The percentage of cells expressing all considered antigens was determined by flow cytometry analysis (CyAn, Beckman Coulter). Properly conjugated isotype matched antibodies were used as negative controls.
Filipin staining was performed using the method described by Blanchette-Mackie et al. . Briefly, cells grown on coverslips, were incubated in serum free medium for 24 hours and then treated for 24 hours with LDL enriched medium. Cells were rinsed with PBS and fixed with 3% paraformaldehyde. After washing them with PBS, the cells were incubated with 1.5 mg of glycine/ml PBS for 10 minutes, stained with filipin (0.05 mg/ml, in PBS 10% FCS) for 2 hours and examined using a Zeiss fluorescence microscope.
Periodic acid Schiff staining (PAS)
PAS was employed to detect glycogen accumulation. Slides were oxidized in 1% periodic acid for 5 minutes, rinsed three times in distilled water and treated with Schiff’s reagent for 25 minutes. After extensive washing, slides were stained with Mayer’s hematoxylin for 10 minutes.
Protein markers: Cells were grown on coverslips then fixed in 4% paraformaldehyde for 20 minutes at room temperature, permeabilized 10 minutes at room temperature with 0.1% Triton X-100 (Sigma-Aldrich) and stained overnight at 4°C to visualize stem cell markers: Oct4 (Abcam, Rabbit polyclonal, 1:150), Nanog (Abcam, Rabbit polyclonal, 1:200), Sox2 (Millipore, Mouse monoclonal, 1:200), Nestin (Millipore, 1:100); myocytes specific markers: smooth muscle actin (SMA) (Sigma, 1:50 mouse monoclonal) and α-sarcomeric actin (ASA) (Sigma, 1:100 mouse monoclonal); endothelial cell marker: CD31 (Dako, 1:50 mouse monoclonal); hepatic specific marker: cytokeratins 8, 18, and 19 (CK) (1:50 mouse monoclonal); or neural specific markers: tubulin beta 3 (COVANCE, 1:1000 mouse monoclonal), NeuN, (Millipore, 1:50 mouse monoclonal) and MAP2 (Millipore, 1:50 rabbit polyclonal). Secondary antibody staining was done with donkey anti-rabbit or donkey anti-mouse antibodies (Alexa-Fluor 555 or 488, Molecular Probes) at 1:600 dilutions. Images were obtained with a live cell imaging dedicated system consisting of a Leica DMI 6000B microscope connected to a Leica DFC350FX camera (Leica Microsystems); 10X (numerical aperture: 0.25), 40X oil immersion (numerical aperture: 1.25) and 63X oil immersion (numerical aperture: 1.40) objectives were employed.
GM2 and GM3 analysis: The analysis of GM2 and GM3 gangliosides was performed as previously described . Cells were grown on coverslips then fixed in 4% paraformaldehyde for 45 minutes at room temperature. Cells were then incubated at room temperature for 1 hour in blocking buffer [PBS with 10% normal donkey serum (NDS) and 0.02% saponin (Sigma-Aldrich)] and stained overnight at 4°C with mouse anti-GM2 (1:20 in blocking buffer) or mouse anti-GM3 (1:20 in blocking buffer). Cells were then incubated with a TRITC conjugated donkey anti-mouse IgM [1:80 in PBS with 2% NDS and 0.02% saponin (Sigma-Aldrich)]. For colocalization studies, a monoclonal anti-LIMP-1 (Novus Biologicals, Littleton, USA) was used as a primary antibody, and an Alexa fluor-conjugated anti-mouse (Invitrogen, Carlsbad, CA, USA) as a secondary antibody.
In all cases, nuclei were stained by DAPI (Vector Laboratories, Inc) and Vectashield (Vector) was used as mounting medium. Epifluorescence and phase contrast images were obtained with a live cell imaging dedicated system consisting of a Leica DMI 6000B microscope connected to a Leica DFC350FX camera (Leica Microsystems); 10X (numerical aperture: 0.25), 40X oil immersion (numerical aperture: 1.25) and 63X oil immersion (numerical aperture: 1.40) objectives were employed. Adobe Photoshop software was utilized to compose and overlay the images, and adjust contrast (Adobe, USA). The counts of positive cells were done manually, considering, where possible, 100 positive events per sample.
Total RNA was extracted from both non-confluent cultures of undifferentiated and differentiated cells at P3 using the TRIzol Reagent (Invitrogen). After treatment with DNase I (Ambion), first strand cDNA synthesis was performed with 1 μg total RNA using random hexanucleotides and MMLV reverse transcriptase (Invitrogen). Primers were designed from available human sequences using the primer analysis software Primer3 (Additional file 1: Table S1). Quantitative RT-PCR was performed using Roche LightCycler 480 Real-Time PCR System and the LightCycler 480 SYBR Green I Master (Roche), following manufacturer’s instructions. GAPDH was used as internal control for normalization. LightCycler 480 Basic software (Roche) utilized the second derivative maximum method to identify the crossing point (Cp).
Evaluation of apoptosis
Apoptosis in differentiated cells at P3 was evaluated by staining of phosphatidylserine exposed on cell membranes with FITC labeled Annexin V, according to the manufacturer’s instructions (Sigma-Aldrich) and analyzed by flow cytometry using a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA).
Morphological analysis data were collected by using the BD Pathway bioimaging platform. Differentiated cells were first immunostained for the neural marker MAP-2, then images were acquired on a BD Pathway 855 using a 20X objective (0.75 NA) in the form of 2 × 2 montage. The images were then analyzed using BD’s Neurite Outgrowth Algorithm that automatically measure parameters describing neurite outgrowth.
Statistical analysis was performed using Student’s t test or one-way ANOVA test, followed by Bonferroni post-test. The analyses were carried out using the software Prism, version 4.0c, GraphPad Software, San Diego, CA, USA; JMP7, SAS Institute Inc., Cary, NC, USA.
p<0.05 was considered statistically significant.
Stem cell characterization
In order to isolate multipotent stem cells from NPC patient samples, we applied a protocol that was optimized for the growth of widely multipotent cells with mesenchymal features (named human multipotent adult stem cells-hMASC) from several human tissues [19, 20] to both freshly obtained skin biopsies and previously established skin fibroblast cultures. If successful, this latter strategy would allow us to derive multipotent cells from already available bio-repositories of cell lines, obtained from patients suffering from rare diseases, such as NPC, for diagnostic purposes.
Surface immunophenotype of stem cells isolated from skin biopsies or culture fibroblasts
Healthy donor (skin biopsy)
NP-C (skin biopsy)
Healthy donor (fibroblast culture)
NP-C (fibroblast culture)
95.9 ± 3.2
99.89 ± 0.22
99.1 ± 0.7
99.9 ± 0.08
37.5 ± 7.2
48.6 ± 0.4
6.38 ± 2.51
54.18 ± 3.44
96.48 ± 2.8
99.21 ± 0.3
99.98 ± 0.1
99.95 ± 0.2
43.33 ± 12.5
62.75 ± 1.05
17.05 ± 14.7
17.62 ± 4.9
1.57 ± 0.7
1.14 ± 0.02
1.81 ± 0.06
1.37 ± 0.25
0.22 ± 0.1
0.16 ± 0.01
0.081 ± 0.06
0.18 ± 0.05
77.8 ± 13
98 ± 0.4
55.5 ± 20.7
96.05 ± 1.2
1.23 ± 0.7
3.04 ± 0.05
0.72 ± 0.7
0.28 ± 0.23
2.06 ± 0.34
5.88 ± 0.28
0.31 ± 0.08
0.23 ± 0.12
2.95 ± 1.33
0.2 ± 0.071
0.37 ± 0.31
0.89 ± 0.24
95.89 ± 2.7
97.25 ± 0.2
99.41 ± 0.7
98.94 ± 1.02
87 ± 3.4
85.9 ± 2.78
92.73 ± 4.35
74.92 ± 30.8
97.12 ± 3.2
98.88 ± 1.41
99.52 ± 0.28
96.25 ± 3.7
92.9 ± 3.7
99.75 ± 0.08
99.48 ± 0.4
99.7 ± 0.19
3.7 ± 1.7
1.9 ± 0.1
0.205 ± 0.12
0.66 ± 0.83
0.1 ± 0.2
0.19 ± 0.01
0.45 ± 0.04
0.07 ± 0.02
3.12 ± 1.1
1.47 ± 0.03
1.92 ± 2.18
1.53 ± 0.18
98.49 ± 3.7
98.4 ± 1.9
99.78 ± 0.21
99.88 ± 0.15
1.1 ± 0.67
0.52 ± 0.03
0.15 ± 0.13
0.27 ± 0.3
0.37 ± 0.1
0.12 ± 0.14
0.65 ± 1.01
0.03 ± 0.01
Cultured cells were then evaluated for the expression of stem cell markers, such as the pluripotent state specific transcription factors Oct-4, Nanog and Sox-2 and the intermediate filament nestin. As shown in Figure 1F-K, the vast majority of cells (65 to 90%) expressed these markers and this expression was independent from the disease state. In fact, no significant differences were observed between NPC and normal cells or between cells isolated from both skin biopsies and early passages of fibroblast cell lines.
In order to investigate whether the pathologic phenotype was retained in these cells, the intracellular accumulation of unesterified cholesterol was analyzed by filipin staining. A massive accumulation of cholesterol within the endosomal/lysosomal compartment was observed in cells isolated from either skin biopsies or fibroblast cultures of NPC patients (Figure 1L-N).
Therefore, in the light of these data, we decided to further characterize stem cells derived from already established skin fibroblast cultures and use them to develop a neuronal differentiation model.
Altogether these results indicate that cells obtained from fibroblast cultures of healthy controls and NPC patients exhibited almost an identical mesenchymal stem cell immunophenotype, expressed pluripotent state specific transcription factors, were clonogenic and multipotent; therefore, in analogy with our previous studies, we named them hSKIN-MASC.
Twenty-four hours after the induction of neural differentiation, hSKIN-MASC showed remarkable morphologic changes. As shown in Figure 2 (panels A-B) differentiated cells displayed an enlargement of the cellular bodies and the presence of long projections, closely resembling the morphology of neuronal cells. Importantly, the morphology of differentiated cells obtained from NPC patients and healthy donors was clearly distinct. In fact, with respect to healthy donors (Figure 2A), differentiated cells obtained from NPC patients (Figure 2B) were larger and presented numerous projections similar to dendrites.
Upon differentiation, a large fraction of hSKIN-MASC became positive to markers of the neuronal lineage. In particular, they expressed NeuN (Figure 2C-E), a neuronal specific nuclear protein, and MAP2 (Figure 2F-H), a structural protein specifically present in neuronal cells. Interestingly, the percentage of cells expressing NeuN was significantly lower in cells derived from NPC patients than in cells derived from healthy donors. In addition, differentiated cells did not express markers associated with glial differentiation, such as glial fibrillary acidic protein (GFAP) and oligodendroglial protein 4 (O4) (data not shown). These data suggest that the differentiation protocol described here specifically favored the differentiation towards the neuronal lineage. It is worth noting that, after differentiation, the cells became negative for the pluripotent state specific transcription factors Oct-4, Nanog and Sox-2, while the expression of nestin was maintained throughout the differentiation process.
To further characterize the type of neuronal cells obtained, mRNA expression of specific markers of dopaminergic (tyrosine hydroxylase, TH and dopamine transporter, DAT), cholinergic (choline acetyltransferase, CHAT) and GABAergic (glutamic acid decarboxylase, GAD) neurons were analyzed by real time PCR. None of these markers were detected in undifferentiated cells. After differentiation, both cells derived from healthy donors and NPC patients expressed similar levels of CHAT mRNA (Additional file 4: Figure S3), while the levels of TH, DAT and GAD mRNA were undetectable.
No differences in the levels of apoptosis have been detected between differentiated cells derived from healthy donors and NPC patients (Additional file 5: Figure S4).
Morphologic analysis of neuronal cells
The remarkable advances in the ability to obtain stem cells from different tissues, including skin (reviewed in [13, 14] and ), which are able to differentiate into several cell lineages, offer the possibility to generate cells with neuronal characteristics from easily accessible sources.
It is conceivable then to develop human cellular models for the study of neurodegenerative diseases harvesting cells from skin biopsies of affected patients and committing them to a neuronal fate, thus paving the way to the study of pathways involved in the development of neurological diseases at the cellular level.
NPC is a genetic severe neurodegenerative disease characterized by the accumulation of cholesterol and other lipids within the late endosomes and lysosomes. Although the neuronal degeneration is the main feature in NPC patients, the molecular pathways linking the lipid accumulation and cellular damage in the central nervous system are largely unknown.
Therefore, we developed a human neuronal model of NPC disease using a method based on the induction of neuronal differentiation of stem cells isolated from skin biopsies or primary cultures of fibroblasts obtained from NPC patients.
Here, we demonstrated that it is possible to isolate clonogenic adult stem cells expressing mesenchymal and pluripotent state associated markers both from skin biopsies and fibroblast cultures. In analogy with the multipotent adult stem cells that we have previously isolated from several adult human tissues, these cells were widely multipotent, being able to differentiate into derivatives of the three germ layers [19, 20]. For these reasons we named them hSKIN-MASC. The fact that we could obtain multipotent stem cells only from early passages of fibroblasts suggests that immature progenitors may be retained in those cultures but are lost upon serial expansion in vitro.
In particular, cells differentiated to neuronal fate expressed markers of mature neurons (NeuN and MAP2) and displayed morphological features resembling neuronal cells. It is worth to highlight that nestin, a marker of the early ectoderm lineage, was expressed both in neural stem cells and in hSKIN-MASC. These data suggest that hSKIN-MASC may represent a population of cells that share some features with the ectoderm lineage. This observation also suggests a common origin between hSKIN-MASC and Skin-derived Precursors or SKP, a multipotent cell population isolated from human dermis that shows a differentiation potential towards both mesenchymal and neural lineages. SKP are believed to be of neural-crest origin  and are retained throughout adulthood, although they decrease with age .
A preliminary characterization of the type of neuronal cells generated by this method, suggests that under the experimental conditions described, hSKIN-MASCs differentiated to cholinergic but not to dopaminergic or GABAergic neurons.
Differentiated cells obtained from NPC patients showed some characteristic features of NPC phenotype. They accumulate unesterified cholesterol and GM2 ganglioside. The accumulation of GM2 ganglioside observed in the differentiated cells but not in fibroblasts or undifferentiated hSKIN-MASC, is consistent with data previously reported in NPC patients and NPC mouse models [10, 12, 26–29]. However, while these studies reported that NPC neuronal cells also accumulate relevant amounts of GM3 ganglioside, no significant accumulation of this ganglioside was found in our model. Since it has been described that the accumulation of GM2 in the brain precedes the accumulation of GM3 , it is possible to hypothesize that the model developed here recapitulates the early stage of the disease.
Furthermore, differentiated cells obtained from NPC patients displayed morphological features that are clearly different from those observed in cells obtained from healthy donors, such as the presence of longer neurites and a greater number of neurite extremities, segments, roots and node points. Interestingly, a distortion of the neuronal shape and an extensive growth of new ectopic neurites have been observed in cortical neurons obtained from human patients or animal models of NPC [29, 30]. In addition, although there is no clear loss of cholinergic neurons in NPC mice, it has been shown that in these animals cholinergic neurons display several morphological alterations .
The identification of morphological alterations in differentiated NPC cells that seem to recapitulate what has been described in human cortical NPC neurons is certainly fascinating. However, we cannot exclude that this phenotype is secondary to an impaired/altered differentiation of MASC isolated from NPC patients. Indeed, the lower percentage of cells expressing NeuN obtained after differentiation of hSKIN-MASC isolated from NPC patients seems to support this hypothesis. Further studies are planned to dissect the molecular mechanisms involved in this phenomenon.
Recently, two human cellular models of NPC disease have been developed by the specific silencing of NPC1 gene in the SH-SY5Y cells line  or in human embryonic stem cells . Both models recapitulate the NPC biochemical phenotype. Although neuronal models obtained through the down-regulation of NPC1 expression in human cells may be useful to analyze some aspects of NPC pathogenesis, they are not suitable for the analysis of the impact of specific mutations on the pathologic phenotype or for testing mutation specific therapeutic strategies.
The model described here offers three main advantages with respect to the models cited above: 1-it was developed directly from patient’s cells and therefore it would be useful to analyze the effect of specific NPC1 mutations within the context of the patient genetic/epigenetic background; 2-it was obtained through the differentiation of cells obtained from accessible sources, such as patients cultured fibroblasts, usually available in many laboratories for diagnostic purposes; 3-it did not involve the forced expression of transgenes in target cells, thus avoiding confounding results due to the reprogramming process.
We have demonstrated that it is possible to isolate stem cells from skin biopsies or fibroblasts in culture and to commit them to a neuronal lineage. Differentiated cells obtained from NPC patients present the main features of NPC disease. Therefore, this model will be useful to study the molecular basis of NPC neurodegeneration and might represent a powerful tool to perform drug screening on cells obtained from NPC patients presenting different genotypes. In addition, the strategy described here may be applied to easily generate human neuronal models of other neurodegenerative diseases.
Niemann Pick C
Multipotent adult stem cells
Fetal bovine serum
Dolbecco’s Modified Eagle Medium
Albumin from bovine serum
Platelet derived growth factor
Epidermal growth factor
Basic fibroblast growth factor
Vascular endothelial growth factor
Insulin-like growth factor 1
Hepatocyte growth factor
Normal donkey serum
Periodic acid Schiff staining
Platelet endothelial cell adhesion molecule
Smooth muscle actin
Microtubule-associated protein 2
Glial fibrillary acidic protein
Oligodendroglial protein 4
Glutamic acid decarboxylase
Human multipotent adult stem cells
Human multipotent adult stem cells derived from skin biopsies and fibroblast cultures
The authors would like to thank Dr. Konstantin Dobrenis for providing anti- GM2 and anti-GM3 antibodies. This work was supported by the Italian Association of Niemann Pick,a grant from the Italian Health Ministry “Role of protein misfolding in the pathogenesis of Niemann-Pick type C disease:a possible therapeutic target (RF-2009-1524462)” and a grant from Italian Health Ministry GR-2007-683407.
- Patterson M, Vanier MT, Suzuki K, Morris ED, Cartsea EB, Neufeld EJ, Blanchette-Mackie PG, Pentchev : Niemann Pick disease type C: a lipid trafficking disorder. The metabolic and molecular basis of inherited diseases, Volume 3. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D. 2001, New York: Mc Graw-Hill, 611-634. VIIGoogle Scholar
- Vanier MT, Millat G: Niemann-Pick disease type C. Clin Genet. 2003, 64: 269-281. 10.1034/j.1399-0004.2003.00147.x.PubMedView ArticleGoogle Scholar
- Carstea ED, Polymeropoulos MH, Parker CC, Detera-Wadleigh SD, O'Neill RR, Patterson MC, Goldin E, Xiao H, Straub RE, Vanier MT, Roscoe OB, Pentchev PG: Linkage of Niemann-Pick disease type C to human chromosome 18. Proc Natl Acad Sci U S A. 1993, 90: 2002-2004. 10.1073/pnas.90.5.2002.PubMed CentralPubMedView ArticleGoogle Scholar
- Vanier MT, Duthel S, Rodriguez-Lafrasse C, Pentchev P, Carstea ED: Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis. Am J Hum Genet. 1996, 58: 118-125.PubMed CentralPubMedGoogle Scholar
- Davies JP, Ioannou YA: Topological analysis of Niemann-Pick C1 protein reveals that the membrane orientation of the putative sterol-sensing domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and sterol regulatory element binding protein cleavage-activating protein. J Biol Chem. 2000, 275: 24367-24374. 10.1074/jbc.M002184200.PubMedView ArticleGoogle Scholar
- Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, Jadot M, Lobel P: Identification of HE1 as the second gene of Niemann-Pick C disease. Science. 2000, 290: 2298-2301. 10.1126/science.290.5500.2298.PubMedView ArticleGoogle Scholar
- Boothe AD, Kruth HS, Weintroub H, Stivers J, Brady RO: A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol. J Biol Chem. 1984, 259: 5784-5791.PubMedGoogle Scholar
- Maue RA, Burgess RW, Wang B, Wooley CM, Seburn KL, Vanier MT, Rogers MA, Chang CC, Chang TY, Harris BT, Graber DJ, Penatti CA, Porter DM, Szwergold BS, Henderson LP, Totenhagen JW, Trouard TP, Borbon IA, Erickson RP: A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations. Hum Mol Genet. 2012, 21: 730-750. 10.1093/hmg/ddr505.PubMed CentralPubMedView ArticleGoogle Scholar
- Love S, Bridges LR, Case CP: Neurofibrillary tangles in Niemann-Pick disease type C. Brain. 1995, 118: 119-129. 10.1093/brain/118.1.119.PubMedView ArticleGoogle Scholar
- Walkley SU, Suzuki K: Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta. 2004, 1685: 48-62. 10.1016/j.bbalip.2004.08.011.PubMedView ArticleGoogle Scholar
- Vance JE, Karten B, Hayashi H: Lipid dynamics in neurons. Biochem Soc Trans. 2006, 34: 399-403. 10.1042/BST0340399.PubMedView ArticleGoogle Scholar
- Zervas M, Somers KL, Thrall MA, Walkley SU: Critical role for glycosphingolipids in Niemann–Pick disease type C. Curr Biol. 2001, 11: 1283-1287. 10.1016/S0960-9822(01)00396-7.PubMedView ArticleGoogle Scholar
- Beltrami AP, Cesselli D, Beltrami CA: Pluripotency rush! Molecular cues for pluripotency, genetic reprogramming of adult stem cells, and widely multipotent adult cells. Pharmacol Ther. 2009, 124: 23-30. 10.1016/j.pharmthera.2009.06.003.PubMedView ArticleGoogle Scholar
- Ratajczak MZ, Zuba-Surma E, Kucia M, Poniewierska A, Suszynska M, Ratajczak J: Pluripotent and multipotent stem cells in adult tissues. Adv Med Sci. 2012, 57: 1-17.PubMedView ArticleGoogle Scholar
- Kern S, Eichler H, Stoeve J, Klüter H, Bieback K: Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006, 24: 1294-1301. 10.1634/stemcells.2005-0342.PubMedView ArticleGoogle Scholar
- Anghileri S, Marconi S, Pignatelli A, Cifelli P, Galié M, Sbarbati A, Krampera M, Belluzzi O, Bonetti B: Neuronal differentiation potential of human adipose-derived mesenchymal stem cells. Stem Cells Dev. 2008, 17: 909-916. 10.1089/scd.2007.0197.PubMedView ArticleGoogle Scholar
- Seo MJ, Suh SY, Bae YC, Jung JS: Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res Commun. 2005, 328: 258-264. 10.1016/j.bbrc.2004.12.158.PubMedView ArticleGoogle Scholar
- Case J, Horvath TL, Ballas CB, March KL, Srour EF: In vitro clonal analysis of murine pluripotent stem cells isolated from skeletal muscle and adipose stromal cells. Exp Hematol. 2008, 36: 224-234. 10.1016/j.exphem.2007.09.003.PubMed CentralPubMedView ArticleGoogle Scholar
- Beltrami AP, Cesselli D, Bergamin N, Marcon P, Rigo S, Puppato E, D'Aurizio F, Verardo R, Piazza S, Pignatelli A, Poz A, Baccarani U, Damiani D, Fanin R, Mariuzzi L, Finato N, Masolini P, Burelli S, Belluzzi O, Schneider C, Beltrami CA: Multipotent cells can be generated in vitro from several adult human organs (heart, liver and bone marrow). Blood. 2007, 110: 3438-3446. 10.1182/blood-2006-11-055566.PubMedView ArticleGoogle Scholar
- Cesselli D, Beltrami AP, Rigo S, Bergamin N, D'Aurizio F, Verardo R, Piazza S, Klaric E, Fanin R, Toffoletto B, Marzinotto S, Mariuzzi L, Finato N, Pandolfi M, Leri A, Schneider C, Beltrami CA, Anversa P: Multipotent progenitor cells are present in human peripheral blood. Circ Res. 2009, 104: 1225-1234. 10.1161/CIRCRESAHA.109.195859.PubMedView ArticleGoogle Scholar
- Blanchette-Mackie EJ, Dwyer NK, Amende LM, Kruth HS, Butler JD, Sokol J, Comly ME, Vanier MT, August JT, Brady RO: Type-C Niemann-Pick disease: low density lipoprotein uptake is associated with premature cholesterol accumulation in the Golgi complex and excessive cholesterol storage in lysosomes. Proc Natl Acad Sci U S A. 1988, 85: 8022-8026. 10.1073/pnas.85.21.8022.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhou S, Davidson C, McGlynn R, Stephney G, Dobrenis K, Vanier MT, Walkley SU: Endosomal/lysosomal processing of gangliosides affects neuronal cholesterol sequestration in Niemann-Pick disease type C. Am J Pathol. 2011, 179: 890-902. 10.1016/j.ajpath.2011.04.017.PubMed CentralPubMedView ArticleGoogle Scholar
- Hunt DP, Jahoda C, Chandran S: Multipotent skin-derived precursors: from biology to clinical translation. Curr Opin Biotechnol. 2009, 20: 522-530. 10.1016/j.copbio.2009.10.004.PubMedView ArticleGoogle Scholar
- Fernandes KJ, McKenzie IA, Mill P, Smith KM, Akhavan M, Barnabé-Heider F, Biernaskie J, Junek A, Kobayashi NR, Toma JG, Kaplan DR, Labosky PA, Rafuse V, Hui CC, Miller FD: A dermal niche for multipotent adult skin-derived precursor cells. Nat Cell Biol. 2004, 6: 1082-1093. 10.1038/ncb1181.PubMedView ArticleGoogle Scholar
- Gago N, Perez-Lopez V, Sanz-Jaka JP, Cormenzana P, Eizaguirre I, Bernad A, Izeta A: Age-dependent depletion of human skin-derived progenitor cells. Stem Cells. 2009, 27: 1164-1172. 10.1002/stem.27.PubMedView ArticleGoogle Scholar
- Elleder M, Jirasek A, Smid F, Ledvinova J, Besley GTN: Niemann–Pick disease Type C: study on the nature of the cerebral storage process. Acta Neuropathol (Berl). 1985, 66: 325-336. 10.1007/BF00690966.View ArticleGoogle Scholar
- Vanier MT: Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem Res. 1999, 24: 481-489. 10.1023/A:1022575511354.PubMedView ArticleGoogle Scholar
- Sleat DE, Wiseman JA, El-Banna M, Price SM, Verot L, Shen MM, Tint GS, Vanier MT, Walkley SU, Lobel P: Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc Natl Acad Sci USA. 2004, 101: 5886-5891. 10.1073/pnas.0308456101.PubMed CentralPubMedView ArticleGoogle Scholar
- March PA, Thrall MA, Brown DE, Mitchell TW, Lowenthal AC, Walkley SU: GABAergic neuroaxonal dystrophy and other cytopathological alterations in feline Niemann-Pick disease type C. Acta Neuropathol. 1997, 94: 164-172. 10.1007/s004010050689.PubMedView ArticleGoogle Scholar
- Zervas M, Dobrenis K, Walkley SU: Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol. 2001, 60: 49-64.PubMedGoogle Scholar
- German DC, Quintero EM, Liang CL, Ng B, Punia S, Xie C, Dietschy JM: Selectiveneurodegeneration, without neurofibrillary tangles, in a mouse model of Niemann-Pick C disease. J Comp Neurol. 2001, 433: 415-425. 10.1002/cne.1149.PubMed CentralPubMedView ArticleGoogle Scholar
- Rodríguez-Pascau L, Coll MJ, Casas J, Vilageliu L, Grinberg D: Generation of a human neuronal stable cell model for Niemann-pick C disease by RNA interference. JIMD Reports. 2012, 4: 29-37.PubMed CentralPubMedView ArticleGoogle Scholar
- Ordonez MP, Roberts EA, Kidwell C, Yuan S, Plaisted W, Goldstein LS: Disruption and therapeutic rescue of autophagy in a human neuronal model of Niemann Pick type C1. Hum Mol Genet. 2012, 21: 2651-2662. 10.1093/hmg/dds090.PubMed CentralPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.